Evidence map›Paper›PMID 41003968›Full record

ArticleRheumatology and therapy2025

Letter to the Editor Regarding "Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases".

Claudia A Salinas, Anthony Louder, Jennifer Polinski, Tancy C Zhang, Hannah Bower, Syd Phillips, Yufei Song, Emaan Rashidi, Rafia Bosan, Hsiu-Ching Chang and 15 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Claudia A SalinasEli Lilly and Company Corporate Center, 893 Delaware St, Indianapolis, IN, 46225, USA. claudia.salinas@lilly.com.
Anthony LouderAetion, New York, NY, USA.
Jennifer PolinskiAetion, New York, NY, USA.
Tancy C ZhangAetion, New York, NY, USA.
Hannah BowerClinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Syd PhillipsIQVIA, Epidemiology and Drug Safety, IQVIA, Durham, NC, USA.
Yufei SongIQVIA, Epidemiology and Drug Safety, IQVIA, Durham, NC, USA.
Emaan RashidiIQVIA, Epidemiology and Drug Safety, IQVIA, Durham, NC, USA.
Rafia BosanIQVIA, Epidemiology and Drug Safety, IQVIA, Durham, NC, USA.
Hsiu-Ching ChangIQVIA, Epidemiology and Drug Safety, IQVIA, Durham, NC, USA.
Nicole FosterThermo Fisher Scientific Inc. (Formerly CorEvitas), Waltham, MA, USA.
Bernice GershensonThermo Fisher Scientific Inc. (Formerly CorEvitas), Waltham, MA, USA.
Hisashi YamanakaRheumatology, Sanno Medical Center, Tokyo, Japan.
Mitsumasa KishimotoDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
Yoshiya TanakaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Peter FischerEli Lilly and Company Corporate Center, 893 Delaware St, Indianapolis, IN, 46225, USA.
Baojin ZhuEli Lilly and Company Corporate Center, 893 Delaware St, Indianapolis, IN, 46225, USA.
Douglas FariesEli Lilly and Company Corporate Center, 893 Delaware St, Indianapolis, IN, 46225, USA.
Xiaodan MaiHealthCore Inc., Wilmington, DE, USA.
Brett T DohertyHealthCore Inc., Wilmington, DE, USA.
Angela GrelaudBordeaux PharmacoEpi, INSERM CIC-P 1401, University of Bordeaux, Bordeaux, France.
Nicolas H ThurinBordeaux PharmacoEpi, INSERM CIC-P 1401, University of Bordeaux, Bordeaux, France.
Johan AsklingClinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Walter DeberdtEli Lilly and Company Corporate Center, 893 Delaware St, Indianapolis, IN, 46225, USA.
B023 Study Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BaricitinibMajor adverse cardiovascular eventRheumatoid arthritisSerious infectionTumor necrosis factor inhibitorsVenous thromboembolism

Identifiers

PMID41003968
PMCPMC12638479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.